Chemistry of Ophthalmic Preparations: Proper Use, Formulation Errors and Recent Advances

Abstract

Topical ophthalmic medications are among the most frequently used therapeutic modalities in the management of ocular diseases. However, the clinical effectiveness of topical ophthalmic formulations depends not only on their pharmacological properties but also on correct administration techniques and patient adherence. Owing to the physiological barriers of the eye and the rapid elimination of drugs, the bioavailability of topically administered ophthalmic agents is inherently limited, and improper application further exacerbates this limitation. Clinical studies have demonstrated that a substantial proportion of patients do not use topical ophthalmic formulations as recommended, leading to treatment failure, an increased risk of systemic adverse effects, and reduced patient compliance. In this review, the pharmacokinetic characteristics of topical ophthalmic formulations and the ocular barriers affecting drug delivery are discussed in detail. Principles of correct administration are comprehensively evaluated, and common application errors encountered in clinical practice are addressed. In addition, the potential adverse effects of preservatives commonly used in ophthalmic formulations, particularly benzalkonium chloride, on the ocular surface, as well as their impact on patient comfort and treatment adherence, are reviewed. The importance of patient education and regular clinical follow-up in achieving therapeutic success is emphasized. Furthermore, current and future strategies, including sustained-release drug delivery systems, drug loaded contact lenses, and digitally assisted applications, are discussed. In conclusion, proper use of topical ophthalmic formulations represents a fundamental determinant of the effectiveness of ophthalmic treatments. Improving clinical results and minimizing complications can be achieved by prioritizing thorough patient counseling, selecting non-preserved medications for suitable individuals, and adopting modernized administration technologies within medical routines.

Keywords

• Drug delivery systems
• topical ophthalmic formulations
• ocular surface
• topical ophthalmic therapy

References

1. Albietz, J. M., & Bruce, A. S. (2001). Conjunctival epithelium in dry eye subtypes: Effects of preserved and non-preserved topical treatments. Current Eye Research, 22(1), 8–18.
2. Alhalafi, A. M. (2017). Applications of polymers in intraocular drug delivery systems. Oman Journal of Ophthalmology, 10(1), 3–8.
3. Anitua, E., Muruzabal, F., Tayebba, A., Riestra, A., Perez, V. L., & Merayo-Lloves, J. (2015). Autologous serum and plasma rich in growth factors in ophthalmology: Preclinical and clinical studies. Acta Ophthalmologica, 93(8), e605–e614.
4. Brown, M. M., Brown, G. C., & Spaeth, G. L. (1984). Improper topical self-administration of ocular medication among patients with glaucoma. Canadian Journal of Ophthalmology, 19(1), 2–5.
5. Buzzi, M., Mancini, A., Vitiello, L., Taloni, A., Pintus, B., & Carnevali, A. (2025). Comparison of amniotic membrane extract and insulin eye drops in the management of persistent epithelial defects: A multicenter retrospective study. Clinical Ophthalmology, 19, 4413–4420.
6. Campagna, P., Macri, A., Rolando, M., & Calabria, G. (1997). Effects of chronic preservative-free topical beta-blocker therapy on the ocular surface in glaucoma patients. Acta Ophthalmologica Scandinavica Supplement, 224, 53.
7. De Paiva, C. S., & Pflugfelder, S. C. (2004). Tear clearance implications for ocular surface health. Experimental Eye Research, 78(3), 395–397.
8. Durak, S., Esmaeili Rad, M., Alp Yetisgin, A., Sutova, H. E., Kutlu, O., & Cetinel, S. (2020). Niosomal drug delivery systems for ocular disease—Recent advances and future prospects. Nanomaterials, 10(6), 1191.

9. El Sanharawi, M., Kowalczuk, L., Touchard, E., Omri, S., de Kozak, Y., & Behar-Cohen, F. (2010). Protein delivery for retinal diseases: From basic considerations to clinical applications. Progress in Retinal and Eye Research, 29(6), 443–465.
10. Feghhi, M., Sharif Makhmalzadeh, B., Farrahi, F., Akmali, M., & Hasanvand, N. (2020). Antimicrobial effect and in vivo ocular delivery of ciprofloxacin-loaded liposomes through rabbit’s eye. Current Eye Research, 45(10), 1245–1251.
11. Feldt, J., Donaubauer, A. J., Welss, J., Schneider, U., Gaipl, U. S., & Paulsen, F. (2022). Anti-inflammatory effects of autologous gold-based serum therapy in patients with osteoarthritis. Scientific Reports, 12(1), 3560.
12. Flanagan, J. L., & Willcox, M. D. P. (2009). Role of lactoferrin in the tear film. Biochimie, 91(1), 35–43.
13. Gupta, R., Patil, B., Shah, B. M., Bali, S. J., Mishra, S. K., & Dada, T. (2012). Evaluating eye drop instillation technique in glaucoma patients. Journal of Glaucoma, 21(3), 189–192.
14. Hornof, M., Toropainen, E., & Urtti, A. (2005). Cell culture models of ocular barriers. European Journal of Pharmaceutics and Biopharmaceutics, 60(2), 207–225.
15. Jacob, S., Nair, A.B., Shah, J., Gupta, S., Boddu, SHS., Sreeharsha, N., Joseph, A., Shinu, P., & Morsy, MA. (2022). Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy-An Overview on Recent Advances. Pharmaceutics, 14(3), 533. doi: 10.3390/pharmaceutics14030533. PMID: 35335909; PMCID: PMC8955373.
16. Järvinen, K., Järvinen, T., & Urtti, A. (1995). Ocular absorption following topical application. Advanced Drug Delivery Reviews, 16(1), 3–19.
17. Jones, L., Downie, L. E., Korb, D., Benitez-del-Castillo, J. M., Dana, R., Deng, S. X., Nichols, K. K., Sullivan, D. A., & Craig, J. P. (2017). TFOS DEWS II management and therapy report. The Ocular Surface, 15(3), 575–628.
18. Jumelle, C., Gholizadeh, S., Annabi, N., & Dana, R. (2020). Advances and limitations of drug delivery systems formulated as eye drops. Journal of Controlled Release, 321, 1–22.
19. Kakkar, S., Karuppayil, S. M., Raut, J. S., Giansanti, F., Papucci, L., & Schiavone, N. (2015). Lipid–polyethylene glycol–based ketoconazole nano-ocular formulation. International Journal of Pharmaceutics, 495(1), 276–289.
20. Kathuria, A., Shamloo, K., Jhanji, V., & Sharma, A. (2021). Classification of commercially available artificial tear formulations based on their ingredients: A rational approach to their use. Journal of Clinical Medicine, 10(6), 1289.
21. Kaur, I. P., Garg, A., Singla, A. K., & Aggarwal, D. (2004). Vesicular systems in ocular drug delivery: An overview. International Journal of Pharmaceutics, 269(1), 1–14.
22. Lama, P. J. (2002). Systemic side effects of beta-adrenergic blockers: An evidence-based assessment. American Journal of Ophthalmology, 134(5), 749–760.
23. Lampert, A., Bruckner, T., Haefeli, W. E., & Seidling, H. M. (2019). Improving patients’ eye-drop administration skills: A multicenter parallel-group cluster-randomized controlled trial. PLoS ONE, 14(2), e0212007.
24. Maurice, D. M., & Mishima, S. (1984). Ocular pharmacokinetics. In M. L. Sears (Ed.), Pharmacology of the eye (pp. 19–116). Springer.
25. Moiseev, R. V., Morrison, P. W. J., Steele, F., & Khutoryanskiy, V. V. (2019). Penetration enhancers in ocular drug delivery. Pharmaceutics, 11(7), 321.
26. Murri, M. S., Moshirfar, M., Birdsong, O. C., Ronquillo, Y. C., Ding, Y., & Hoopes, P. C. (2018). Amniotic membrane extract and eye drops: A review of the literature and clinical application. Clinical Ophthalmology, 12, 1105–1112.
27. Nicoli, S., Ferrari, G., Quarta, M., Macaluso, C., Govoni, P., & Dallatana, D. (2009). Porcine sclera as a model of human sclera for in vitro transport experiments. Molecular Vision, 15, 259–266.
28. Olsen, T. W., Edelhauser, H. F., Lim, J. I., & Geroski, D. H. (1995). Human scleral permeability. Investigative Ophthalmology & Visual Science, 36(9), 1893–1903.
29. Onugwu, A.L., Nwagwu, C.S., Onugwu, O.S., Echezona, A.C., Agbo, C.P., Ihim, S.A., Emeh, P., Nnamani, P.O., Attama, A.A., & Khutoryanskiy, V.V. (2023). Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. Journal of Controlled Release, 354, 465-488. https://doi.org/10.1016/j.jconrel.2023.01.018.
30. Peduzzi, M., Debbia, A., & Monzani, A. (1987). Fidia Research Series (Vol. 11). Fidia Research.
31. Pérez, M. L., Barreales, S., Sabater-Cruz, N., Martinez-Conesa, E. M., Vilarrodona, A., & Casaroli-Marano, R. P. (2022). Amniotic membrane extract eye drops: A new approach for severe ocular surface diseases. Cell and Tissue Banking, 23(3), 473–481.
32. Pflugfelder, S. C., & Stern, M. E. (2020). Biological functions of tear film. Experimental Eye Research, 197, 108115. Ragg, S., Key, M., Rankin, F., & WuDunn, D. (2019). The effect of molecular weight on passage of proteins through the blood–aqueous barrier. Investigative Ophthalmology & Visual Science, 60(5), 1461–1469.
33. Roberts, C. W., Carniglia, P. E., & Brazzo, B. G. (2007). Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea, 26(7), 805–809.
34. Sawant, K. K., & Dodiya, S. S. (2008). Recent advances and patents on solid lipid nanoparticles. Recent Patents on Drug Delivery & Formulation, 2(2), 120–135.
35. Shafiq, M., Rafique, M., Cui, Y., & Pan, L., Do, C.W., & Ho, E.A. (2023). An insight on ophthalmic drug delivery systems: Focus on polymeric biomaterials-based carriers. Journal of Controlled Release, 362, 446-467. https://doi.org/10.1016/j.jconrel.2023.08.041
36. Shanley, L. J., McCaig, C. D., Forrester, J. V., & Zhao, M. (2004). Insulin promotes in vitro cell migration. Investigative Ophthalmology & Visual Science, 45(4), 1088–1094.
37. Stern, M. E., Gao, J., Siemasko, K. F., Beuerman, R. W., & Pflugfelder, S. C. (2004). The role of the tear functional unit in dry eye. Experimental Eye Research, 78(3), 409–416.
38. Stringer, W., & Bryant, R. (2010). Dose uniformity of topical corticosteroid preparations. Clinical Ophthalmology, 4, 1119–1124.
39. Swetledge, S., Jung, J. P., Carter, R., & Sabliov, C. (2021). Distribution of polymeric nanoparticles in the eye. Journal of Nanobiotechnology, 19(1), 10.
40. Tatham, A. J., Sarodia, U., Gatrad, F., & Awan, A. (2013). Eye drop instillation technique in patients with glaucoma. Eye, 27(11), 1293–1298.
41. Teuchner, B., Wagner, J., Bechrakis, N. E., Orth-Höller, D., & Nagl, M. (2015). Microbial contamination of glaucoma eyedrops. Medicine, 94(8), e583.
42. Titone, R., Zhu, M., & Robertson, D. M. (2018). Insulin-mediated receptor accumulation. Scientific Reports, 8(1), 1–13.
43. Türkcan, C. (2022). Developing new polymeric nanoparticles for controlled release of quercetin as an alternative material protecting from COVID-19. International Journal of Chemistry and Technology, 6(1), 76-80.
44. Wang, Y., Xu, X., Gu, Y., Cheng, Y., & Cao, F. (2018). Nanoparticle-based topical drug delivery. Expert Opinion on Drug Delivery, 15(7), 687–701.
45. Yasamineh, S., Yasamineh, P., Ghafouri Kalajahi, H., Gholizadeh, O., Yekanipour, Z., Afkhami, H., Eslami, M., Hossein Kheirkhah, A., Taghizadeh, M., Yazdani, Y,, & Dadashpour, M. (2022). A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system. International Journal of Pharmaceutics, 22, 624:121878. doi: 10.1016/j.ijpharm.2022.121878. PMID: 35636629.